Polymorphisms of genes involved in lipid metabolism and risk of chronic kidney disease in Japanese - Cross-sectional data from the J-MICC study

Asahi Hishida, Kenji Wakai, Mariko Naito, Shino Suma, Tae Sasakabe, Nobuyuki Hamajima, Satoyo Hosono, Mikako Horita, Tanvir Chowdhury Turin, Sadao Suzuki, Tara Sefanya Kairupan, Haruo Mikami, Keizo Ohnaka, Isao Watanabe, Hirokazu Uemura, Michiaki Kubo, Hideo Tanaka

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Chronic kidney disease (CKD) is known to be one of the causes of cardiovascular disease and end-stage renal disease. Among the several treatable risk factors of CKD, that of dyslipidemia is relatively controversial. To clarify the association of polymorphisms in genes involved in lipid metabolism with the risk of CKD in the Japanese population, we used cross-sectional data from the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study. Methods: A total of 3,268 men and women, aged 35-69 years, were selected from J-MICC Study participants for inclusion in this study. Twenty-eight candidate single nucleotide polymorphisms (SNPs) were selected in 17 genes associated with the risk of lipid metabolism disorders, and genotyping of the subjects was conducted using the multiplex PCR-based invader assay. The prevalence of CKD was determined for stages 3-5 (defined as estimated glomerular filtration rate <60 ml/min/1.73 m2). Results: Logistic regression analysis revealed that SNPs APOA5 T - 1131C (rs662799), APOA5 T1259C (rs2266788), TOMM40 A/G (rs157580), and CETP TaqIB (rs708272) were significantly associated with CKD risk in those individuals genotyped, with age- and sex-adjusted odds ratios (ORs) per minor allele (and 95% confidence intervals (CIs)) of OR 1.22 (95% CI: 1.06-1.39), 1.19 (1.03-1.37), 1.27 (1.12-1.45), and 0.81 (0.71-0.92), respectively. Analysis of the gene-environment interaction revealed that body mass index (BMI) was a significant effect modifier for APOA5 T - 1131C (rs662799) and a marginally significant effect modifier for APOA5 T/C (rs2266788), with the interaction between BMI ≥30 and individuals with at least one minor allele of each genotype of OR 10.43 (95% CI: 1.29-84.19) and 3.36 (0.87-13.01), respectively. Conclusions: Four polymorphisms in APOA5, TOMM40, and CETP were shown to be significantly associated with CKD risk, and a significant interaction between the two APOA5 SNPs and BMI on CKD risk was also demonstrated. This suggests the future possibility of personalized risk estimation for this life-limiting disease.

Original languageEnglish
Article number162
JournalLipids in Health and Disease
Volume13
Issue number1
DOIs
Publication statusPublished - 14-10-2014

Fingerprint

Polymorphism
Chronic Renal Insufficiency
Lipid Metabolism
Japan
Cohort Studies
Genes
Single Nucleotide Polymorphism
Body Mass Index
Odds Ratio
Confidence Intervals
Nucleotides
Alleles
Lipid Metabolism Disorders
Gene-Environment Interaction
Multiplex Polymerase Chain Reaction
Dyslipidemias
Glomerular Filtration Rate
Chronic Kidney Failure
Cardiovascular Diseases
Logistic Models

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Hishida, Asahi ; Wakai, Kenji ; Naito, Mariko ; Suma, Shino ; Sasakabe, Tae ; Hamajima, Nobuyuki ; Hosono, Satoyo ; Horita, Mikako ; Turin, Tanvir Chowdhury ; Suzuki, Sadao ; Kairupan, Tara Sefanya ; Mikami, Haruo ; Ohnaka, Keizo ; Watanabe, Isao ; Uemura, Hirokazu ; Kubo, Michiaki ; Tanaka, Hideo. / Polymorphisms of genes involved in lipid metabolism and risk of chronic kidney disease in Japanese - Cross-sectional data from the J-MICC study. In: Lipids in Health and Disease. 2014 ; Vol. 13, No. 1.
@article{6fc8043550cf46aeade71de8237e19cc,
title = "Polymorphisms of genes involved in lipid metabolism and risk of chronic kidney disease in Japanese - Cross-sectional data from the J-MICC study",
abstract = "Background: Chronic kidney disease (CKD) is known to be one of the causes of cardiovascular disease and end-stage renal disease. Among the several treatable risk factors of CKD, that of dyslipidemia is relatively controversial. To clarify the association of polymorphisms in genes involved in lipid metabolism with the risk of CKD in the Japanese population, we used cross-sectional data from the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study. Methods: A total of 3,268 men and women, aged 35-69 years, were selected from J-MICC Study participants for inclusion in this study. Twenty-eight candidate single nucleotide polymorphisms (SNPs) were selected in 17 genes associated with the risk of lipid metabolism disorders, and genotyping of the subjects was conducted using the multiplex PCR-based invader assay. The prevalence of CKD was determined for stages 3-5 (defined as estimated glomerular filtration rate <60 ml/min/1.73 m2). Results: Logistic regression analysis revealed that SNPs APOA5 T - 1131C (rs662799), APOA5 T1259C (rs2266788), TOMM40 A/G (rs157580), and CETP TaqIB (rs708272) were significantly associated with CKD risk in those individuals genotyped, with age- and sex-adjusted odds ratios (ORs) per minor allele (and 95{\%} confidence intervals (CIs)) of OR 1.22 (95{\%} CI: 1.06-1.39), 1.19 (1.03-1.37), 1.27 (1.12-1.45), and 0.81 (0.71-0.92), respectively. Analysis of the gene-environment interaction revealed that body mass index (BMI) was a significant effect modifier for APOA5 T - 1131C (rs662799) and a marginally significant effect modifier for APOA5 T/C (rs2266788), with the interaction between BMI ≥30 and individuals with at least one minor allele of each genotype of OR 10.43 (95{\%} CI: 1.29-84.19) and 3.36 (0.87-13.01), respectively. Conclusions: Four polymorphisms in APOA5, TOMM40, and CETP were shown to be significantly associated with CKD risk, and a significant interaction between the two APOA5 SNPs and BMI on CKD risk was also demonstrated. This suggests the future possibility of personalized risk estimation for this life-limiting disease.",
author = "Asahi Hishida and Kenji Wakai and Mariko Naito and Shino Suma and Tae Sasakabe and Nobuyuki Hamajima and Satoyo Hosono and Mikako Horita and Turin, {Tanvir Chowdhury} and Sadao Suzuki and Kairupan, {Tara Sefanya} and Haruo Mikami and Keizo Ohnaka and Isao Watanabe and Hirokazu Uemura and Michiaki Kubo and Hideo Tanaka",
year = "2014",
month = "10",
day = "14",
doi = "10.1186/1476-511X-13-162",
language = "English",
volume = "13",
journal = "Lipids in Health and Disease",
issn = "1476-511X",
publisher = "BioMed Central",
number = "1",

}

Hishida, A, Wakai, K, Naito, M, Suma, S, Sasakabe, T, Hamajima, N, Hosono, S, Horita, M, Turin, TC, Suzuki, S, Kairupan, TS, Mikami, H, Ohnaka, K, Watanabe, I, Uemura, H, Kubo, M & Tanaka, H 2014, 'Polymorphisms of genes involved in lipid metabolism and risk of chronic kidney disease in Japanese - Cross-sectional data from the J-MICC study', Lipids in Health and Disease, vol. 13, no. 1, 162. https://doi.org/10.1186/1476-511X-13-162

Polymorphisms of genes involved in lipid metabolism and risk of chronic kidney disease in Japanese - Cross-sectional data from the J-MICC study. / Hishida, Asahi; Wakai, Kenji; Naito, Mariko; Suma, Shino; Sasakabe, Tae; Hamajima, Nobuyuki; Hosono, Satoyo; Horita, Mikako; Turin, Tanvir Chowdhury; Suzuki, Sadao; Kairupan, Tara Sefanya; Mikami, Haruo; Ohnaka, Keizo; Watanabe, Isao; Uemura, Hirokazu; Kubo, Michiaki; Tanaka, Hideo.

In: Lipids in Health and Disease, Vol. 13, No. 1, 162, 14.10.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Polymorphisms of genes involved in lipid metabolism and risk of chronic kidney disease in Japanese - Cross-sectional data from the J-MICC study

AU - Hishida, Asahi

AU - Wakai, Kenji

AU - Naito, Mariko

AU - Suma, Shino

AU - Sasakabe, Tae

AU - Hamajima, Nobuyuki

AU - Hosono, Satoyo

AU - Horita, Mikako

AU - Turin, Tanvir Chowdhury

AU - Suzuki, Sadao

AU - Kairupan, Tara Sefanya

AU - Mikami, Haruo

AU - Ohnaka, Keizo

AU - Watanabe, Isao

AU - Uemura, Hirokazu

AU - Kubo, Michiaki

AU - Tanaka, Hideo

PY - 2014/10/14

Y1 - 2014/10/14

N2 - Background: Chronic kidney disease (CKD) is known to be one of the causes of cardiovascular disease and end-stage renal disease. Among the several treatable risk factors of CKD, that of dyslipidemia is relatively controversial. To clarify the association of polymorphisms in genes involved in lipid metabolism with the risk of CKD in the Japanese population, we used cross-sectional data from the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study. Methods: A total of 3,268 men and women, aged 35-69 years, were selected from J-MICC Study participants for inclusion in this study. Twenty-eight candidate single nucleotide polymorphisms (SNPs) were selected in 17 genes associated with the risk of lipid metabolism disorders, and genotyping of the subjects was conducted using the multiplex PCR-based invader assay. The prevalence of CKD was determined for stages 3-5 (defined as estimated glomerular filtration rate <60 ml/min/1.73 m2). Results: Logistic regression analysis revealed that SNPs APOA5 T - 1131C (rs662799), APOA5 T1259C (rs2266788), TOMM40 A/G (rs157580), and CETP TaqIB (rs708272) were significantly associated with CKD risk in those individuals genotyped, with age- and sex-adjusted odds ratios (ORs) per minor allele (and 95% confidence intervals (CIs)) of OR 1.22 (95% CI: 1.06-1.39), 1.19 (1.03-1.37), 1.27 (1.12-1.45), and 0.81 (0.71-0.92), respectively. Analysis of the gene-environment interaction revealed that body mass index (BMI) was a significant effect modifier for APOA5 T - 1131C (rs662799) and a marginally significant effect modifier for APOA5 T/C (rs2266788), with the interaction between BMI ≥30 and individuals with at least one minor allele of each genotype of OR 10.43 (95% CI: 1.29-84.19) and 3.36 (0.87-13.01), respectively. Conclusions: Four polymorphisms in APOA5, TOMM40, and CETP were shown to be significantly associated with CKD risk, and a significant interaction between the two APOA5 SNPs and BMI on CKD risk was also demonstrated. This suggests the future possibility of personalized risk estimation for this life-limiting disease.

AB - Background: Chronic kidney disease (CKD) is known to be one of the causes of cardiovascular disease and end-stage renal disease. Among the several treatable risk factors of CKD, that of dyslipidemia is relatively controversial. To clarify the association of polymorphisms in genes involved in lipid metabolism with the risk of CKD in the Japanese population, we used cross-sectional data from the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study. Methods: A total of 3,268 men and women, aged 35-69 years, were selected from J-MICC Study participants for inclusion in this study. Twenty-eight candidate single nucleotide polymorphisms (SNPs) were selected in 17 genes associated with the risk of lipid metabolism disorders, and genotyping of the subjects was conducted using the multiplex PCR-based invader assay. The prevalence of CKD was determined for stages 3-5 (defined as estimated glomerular filtration rate <60 ml/min/1.73 m2). Results: Logistic regression analysis revealed that SNPs APOA5 T - 1131C (rs662799), APOA5 T1259C (rs2266788), TOMM40 A/G (rs157580), and CETP TaqIB (rs708272) were significantly associated with CKD risk in those individuals genotyped, with age- and sex-adjusted odds ratios (ORs) per minor allele (and 95% confidence intervals (CIs)) of OR 1.22 (95% CI: 1.06-1.39), 1.19 (1.03-1.37), 1.27 (1.12-1.45), and 0.81 (0.71-0.92), respectively. Analysis of the gene-environment interaction revealed that body mass index (BMI) was a significant effect modifier for APOA5 T - 1131C (rs662799) and a marginally significant effect modifier for APOA5 T/C (rs2266788), with the interaction between BMI ≥30 and individuals with at least one minor allele of each genotype of OR 10.43 (95% CI: 1.29-84.19) and 3.36 (0.87-13.01), respectively. Conclusions: Four polymorphisms in APOA5, TOMM40, and CETP were shown to be significantly associated with CKD risk, and a significant interaction between the two APOA5 SNPs and BMI on CKD risk was also demonstrated. This suggests the future possibility of personalized risk estimation for this life-limiting disease.

UR - http://www.scopus.com/inward/record.url?scp=84925884248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925884248&partnerID=8YFLogxK

U2 - 10.1186/1476-511X-13-162

DO - 10.1186/1476-511X-13-162

M3 - Article

C2 - 25311932

AN - SCOPUS:84925884248

VL - 13

JO - Lipids in Health and Disease

JF - Lipids in Health and Disease

SN - 1476-511X

IS - 1

M1 - 162

ER -